海翔药业(002099) - 2023 Q3 - 季度财报

Financial Performance - The company reported a net loss of CNY 20,878,787.40 for the quarter, compared to a loss of CNY 68,868,710.95 in the previous period[15]. - The company's operating revenue for the third quarter was ¥480,189,638.76, a decrease of 20.40% compared to the same period last year[33]. - The net profit attributable to shareholders of the listed company was -¥57,759,934.00, representing a decline of 262.91% year-on-year[33]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,881,146.60, down 150.06% from the previous year[33]. - The basic earnings per share for the quarter was -¥0.03, a decrease of 250.00% year-on-year[33]. - The diluted earnings per share for the quarter was also -¥0.03, reflecting a decline of 250.00% compared to the same period last year[33]. - The weighted average return on net assets was -0.95%, a decrease of 1.54 percentage points year-on-year[33]. - The total comprehensive income attributable to the parent company was -38,588,053.71, compared to 206,822,228.52 in the previous period[46]. - Basic and diluted earnings per share were both -0.02, down from 0.13 in the previous period[46]. Assets and Liabilities - Total assets increased to CNY 8,494,578,941.65, up from CNY 8,393,099,770.24, reflecting a growth of approximately 1.3%[21]. - Current assets totaled CNY 3,475,692,833.67, compared to CNY 3,245,690,461.75 in the previous period, indicating an increase of about 7.1%[21]. - Non-current assets decreased to CNY 5,018,886,107.98 from CNY 5,147,409,308.49, a decline of about 2.5%[21]. - Total liabilities increased to CNY 2,322,787,671.53 from CNY 1,970,676,899.34, representing a growth of approximately 17.8%[21]. - The total liabilities increased to CNY 2,510,121,746.59 from CNY 2,288,184,973.02, reflecting a growth in financial obligations[43]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥247,336,979.19, a decrease of 17.57% compared to the same period last year[33]. - Cash flow from operating activities generated a net amount of 247,336,979.19, a decrease from 300,048,831.98 in the previous period[47]. - Cash inflow from investment activities totaled 145,211,433.74, significantly up from 33,656,710.46 in the previous period[47]. - Cash outflow from investment activities was 278,564,270.27, down from 846,940,767.57 in the previous period[47]. - Cash flow from financing activities generated a net amount of 462,600,239.98, slightly down from 477,548,457.08 in the previous period[47]. - The net increase in cash and cash equivalents was 604,289,536.33, compared to 76,205,597.23 in the previous period[47]. - The ending balance of cash and cash equivalents was 1,641,324,262.76, compared to 1,664,213,611.36 in the previous period[47]. - The company received cash from investment income amounting to 24,200,000.00, up from 3,450,399.50 in the previous period[47]. - The company paid cash to employees totaling 245,415,678.65, a decrease from 265,205,841.85 in the previous period[47]. Shareholder Information - The number of common shareholders at the end of the reporting period was 27,030, with the largest shareholder holding 32.37% of the shares[17]. Investment and Development - The company plans to expand its market presence and invest in new product development to enhance future growth prospects[19]. - The company’s long-term investments decreased to CNY 175,173,156.29 from CNY 183,439,777.26, a reduction of about 4.1%[21]. - The company experienced a significant increase in investment income, with a loss of CNY -61,416,890.47, reflecting a 1670.11% increase in losses compared to CNY -3,469,660.05 last year[35]. Operating Costs - Total operating revenue for the third quarter of 2023 was CNY 1,676,630,297.77, a decrease of 19.0% compared to CNY 2,071,095,203.00 in the same period last year[43]. - Total operating costs decreased to CNY 1,659,118,871.86, down 7.6% from CNY 1,795,713,911.58 year-on-year[43]. - Management expenses were CNY 227,190,357.10, a significant reduction of 31.65% compared to CNY 332,414,279.59 in the previous year[43]. - Research and development expenses amounted to CNY 93,277,992.91, down from CNY 109,159,989.58 year-on-year[43].